Table 1.
Characteristics of HIV-infected patients with available pol sequences (2004-2011) according to HIV diagnosis year
| Characteristic | Years of Diagnosis1 | p-value | |||||||
|---|---|---|---|---|---|---|---|---|---|
| All | ≤2003 | 2004-2007 | 2008-2011 | ||||||
| N | % | N | % | N | % | N | % | ||
| Total | 1277 | 619 | 316 | 295 | |||||
| Sex | |||||||||
| Male | 901 | 71% | 410 | 66% | 226 | 72% | 230 | 78% | <0.01 |
| Female | 371 | 29% | 209 | 34% | 85 | 27% | 65 | 22% | |
| Transgender | 5 | 0% | 0 | 0% | 5 | 2% | 0 | 0% | |
| Age at HIV Diagnosis (years) | |||||||||
| 0-29 | 469 | 37% | 295 | 48% | 92 | 29% | 82 | 28% | <0.01 |
| 30-39 | 420 | 33% | 238 | 38% | 102 | 32% | 80 | 27% | |
| ≥40 | 341 | 27% | 86 | 14% | 122 | 39% | 133 | 45% | |
| Unknown | 47 | 4% | |||||||
| Transmission Risk2 | |||||||||
| MSM | 476 | 37% | 164 | 26% | 146 | 46% | 165 | 56% | <0.01 |
| MSF | 166 | 13% | 71 | 11% | 47 | 15% | 48 | 16% | |
| FSM | 212 | 17% | 98 | 16% | 63 | 20% | 51 | 17% | |
| IDU | 245 | 19% | 196 | 32% | 24 | 8% | 23 | 8% | |
| MSM/IDU | 37 | 3% | 23 | 4% | 13 | 4% | 1 | 0% | |
| Perinatal | 31 | 2% | 23 | 4% | 8 | 3% | 0 | 0% | |
| Unknown | 94 | 7% | 32 | 5% | 11 | 3% | 7 | 2% | |
| Other3 | 16 | 1% | 12 | 2% | 4 | 1% | 0 | 0% | |
| Antiretroviral Treatment (at sequencing) | |||||||||
| Naïve | 596 | 47% | 81 | 13% | 244 | 77% | 271 | 92% | <0.01 |
| Experienced4 | 681 | 53% | 538 | 87% | 72 | 23% | 24 | 8% | |
| Transmitted Drug Resistance (of #Naïve) | |||||||||
| Any | 66 | 11% | 8 | 10% | 25 | 10% | 33 | 12% | 0.73 |
| NRTIs | 24 | 4% | 3 | 4% | 8 | 3% | 13 | 5% | 0.67 |
| NNRTIs | 43 | 7% | 4 | 5% | 18 | 7% | 21 | 8% | 0.69 |
| PIs | 10 | 2% | 1 | 1% | 2 | 1% | 7 | 3% | 0.28 |
N=number; MSM=men who have sex with men; MSF=males who have sex with females; FSM=females who have sex with males; IDU=Injection drug use; NRTI=nucleoside reverse transcriptase inhibitors; NNRTI=non-nucleoside reverse transcriptase inhibitors; PI=protease inhibitors.
Forty-seven individuals did not have an available year of diagnosis and are not included in the categorical breakdown.
Transmission risk: MSM includes both MSM and MSM/MSF. IDU includes IDU, IDU/MSF and IDU/FSM.
Other risk factors include two occupational and ten transfusion related infections (≤2003); and four transfusion related infections (2004-2007).
This category also includes individuals who are likely treated but did not have available data.